Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,682 shares of the biopharmaceutical company’s stock after selling 2,964 shares during the quarter. Private Advisor Group LLC’s holdings in Gilead Sciences were worth $3,204,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. HHM Wealth Advisors LLC lifted its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership purchased a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Valued Wealth Advisors LLC boosted its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares in the last quarter. Finally, Crews Bank & Trust acquired a new stake in Gilead Sciences during the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Down 0.1 %

Shares of NASDAQ GILD opened at $109.95 on Monday. The stock has a market cap of $137.03 billion, a P/E ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.18. The business’s fifty day simple moving average is $95.41 and its 200-day simple moving average is $88.83. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $111.03. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 832.43%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 713,000 shares of company stock valued at $67,945,181. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GILD. Truist Financial increased their price target on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Wolfe Research started coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. The Goldman Sachs Group upped their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.